Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Global Trends in R&D 2025

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • IQVIA Connected Intelligence™
  • IQVIA Healthcare-grade AI®
  • IQVIA AI Assistant
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Patient Experience Solutions with Apple devices
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
IQVIA AI is Healthcare-grade AI

Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.

LEARN MORE
Meet the IQVIA AI Assistant

Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.

LEARN MORE
Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
IQVIA Patient Experience Solutions with Apple devices

Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.

LEARN MORE
MAIN/Careers
Careers/
IQVIA Careers
Featured Careers
Stay Connected

WE'RE HIRING

"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.

VIEW ROLES
MAIN/Contact Us
Contact Us/
Blog
The Role of Biomarkers in Non-Small Cell Lung Cancer Treatment
IQVIA Biomarker Link
Daniel Roberts, Associate Director, Offering Management
Mar 20, 2025
  • Blogs
  • The Role of Biomarkers in Non-Small Cell Lung Cancer Treatment

LISTEN TO OR READ THIS BLOG BELOW

IQVIA
The Role of Biomarkers in Non-Small Cell Lung Cancer Treatment

Non-small cell lung cancer (NSCLC) is one of the major cancer types, both in terms of patients treated and drug sales. The treatment landscape for NSCLC has evolved significantly over the past decade, largely due to the launch of biomarker-specific targeted therapies. Biomarkers are biological molecules found in blood, other body fluids, or tissues that are indicative of an abnormal process, condition, or disease. In the context of cancer, biomarkers can provide critical information about the tumor's genetic makeup and can be predictive or prognostic of how the patient responds to treatment, helping to guide personalized treatment strategies.

The Impact of Biomarker Testing

Biomarkers are most commonly used in NSCLC as a predictive test to determine whether patients will respond to treatment. This information helps oncologists select the most effective treatment for each patient. For instance, patients with EGFR mutations or ALK rearrangements can receive targeted therapies that specifically inhibit these genetic drivers, leading to better outcomes and fewer side effects compared to conventional chemotherapy. This also helps biomarker-negative patients avoid the unnecessary side effects of these treatments where they are unlikely to get any benefit.

Key Biomarkers in NSCLC

  1. EGFR (Epidermal Growth Factor Receptor): Mutations in the EGFR gene are found in about 10-15% of NSCLC cases in Western populations and up to 50% in Asian populations. These mutations are more common in non-smokers and women. EGFR mutations can be targeted by tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and osimertinib, which have shown significant efficacy in improving patient outcomes. EGFR-positive patents made up approximately $8bn of total worldwide NSCLC drug sales in 2024 [Source: Biomarker Link].
  2. ALK (Anaplastic Lymphoma Kinase): ALK rearrangements occur in about 5% of NSCLC cases. Patients with ALK-positive tumors can benefit from ALK inhibitors like crizotinib, ceritinib, and alectinib. These targeted therapies have been shown to improve progression-free survival compared to traditional chemotherapy. ALK-positive patents made up approximately $2.5bn of total worldwide NSCLC drug sales in 2024 [Source: Biomarker Link].
  3. ROS1: ROS1 rearrangements are present in about 1-2% of NSCLC cases. Similar to ALK, ROS1-positive tumors respond well to crizotinib and other ROS1 inhibitors (like lorlatinib and entrectinib), offering another targeted treatment option for patients. ROS1-positive patents made up approximately $300m of total worldwide NSCLC drug sales in 2024 [Source: Biomarker Link].
  4. BRAF: Mutations in the BRAF gene, particularly the V600E mutation, are found in about 1-3% of NSCLC cases. BRAF inhibitors, often used in combination with MEK inhibitors, have shown promise in treating BRAF-mutant NSCLC. BRAF-positive patents made up approximately $400m of total worldwide NSCLC drug sales in 2024 [Source: Biomarker Link].
  5. PD-L1 (Programmed Death-Ligand 1): PD-L1 expression is a biomarker used to predict response to immunotherapy. High levels of PD-L1 expression in tumor cells can indicate a better response to immune checkpoint inhibitors such as pembrolizumab and nivolumab. These therapies work by enhancing the body's immune response against cancer cells. However, there are some clinical settings where PD-L1 negative patients can still receive a clinical benefit from these drugs, and there are other clinical settings where PD-L1 expression is not predictive at all the potential clinical efficacy.

Moreover, biomarker testing can identify patients who are eligible for clinical trials of new therapies, providing access to cutting-edge treatments that are not yet widely available. As research continues, new biomarkers and corresponding targeted therapies are likely to emerge, further improving the prognosis for NSCLC patients.

Conclusion

The integration of biomarker testing into the treatment of non-small cell lung cancer represents a significant advancement in oncology. By understanding the genetic underpinnings of each patient's cancer, clinicians can tailor treatments to achieve the best possible outcomes. As the field of biomarker research continues to evolve, it holds the promise of even more personalized and effective cancer therapies in the future.

You may also be interested in

Article
Parkinson's disease: An Analysis on Key Selected Pipeline Developments and Clinical Trial Insights
Institute Report
Global Oncology Trends 2025
White Paper
Evolving Beyond the PBS: Exploring Australia’s Private Medicines Market
Fact Sheet
IQVIA Oncology Dynamics
Blog
Testing of biomarkers in Oncology
Institute Report
Global Oncology Trends 2022
Prev
Next

Related solutions

Contact Us